Loading...

PE anti-mouse CD274 (B7-H1, PD-L1) Antibody PE anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_PE_030308
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
  • 10Fdot9G2_PE_030308
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
124307 25 µg DKK393
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124308 100 µg DKK1147
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  2. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  3. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  4. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  5. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  6. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  7. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  8. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  9. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  10. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  11. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  12. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  13. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  14. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  15. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  16. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  17. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  18. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  19. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  20. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  21. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  22. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  23. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  24. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  25. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  26. Shi J, et al. 2018. Immunity. 49:264. PubMed
  27. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  28. Lu SX, et al. 2021. Cell. . PubMed
  29. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  30. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  31. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  32. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  33. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  34. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  35. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  36. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  37. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  38. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  39. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  40. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  41. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  42. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  43. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  44. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  45. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  46. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  47. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  48. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  49. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  50. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  51. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  52. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  53. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  54. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  55. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  56. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  57. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  58. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  59. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  60. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  61. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  62. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  63. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  64. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  65. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  66. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  67. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  68. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  69. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  70. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  71. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  72. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  73. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  74. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  75. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  76. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  77. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  78. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  79. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  80. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  81. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  82. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  83. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  84. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  85. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  86. Zheng Y, et al. 2022. Transl Res. :. PubMed
  87. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  88. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  89. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  90. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  91. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  92. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  93. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  94. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  95. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  96. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  97. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  98. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  99. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  100. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  101. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  102. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  103. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  104. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  105. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  106. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  107. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  108. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  109. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  110. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  111. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  112. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  113. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  114. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  115. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  116. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  117. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  118. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  119. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  120. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  121. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  122. Shi J, et al. 2018. Immunity. 49:264. PubMed
  123. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  124. Lu SX, et al. 2021. Cell. . PubMed
  125. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  126. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  127. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  128. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  129. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  130. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  131. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  132. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  133. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  134. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  135. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  136. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  137. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  138. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  139. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  140. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  141. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  142. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  143. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  144. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  145. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  146. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  147. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  148. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  149. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  150. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  151. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  152. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  153. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  154. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  155. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  156. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  157. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  158. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  159. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  160. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  161. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  162. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  163. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  164. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  165. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  166. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  167. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  168. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  169. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  170. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  171. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  172. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  173. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  174. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  175. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  176. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  177. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  178. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  179. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  180. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  181. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  182. Zheng Y, et al. 2022. Transl Res. :. PubMed
  183. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  184. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  185. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  186. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  187. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  188. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  189. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  190. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  191. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  192. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_2073557 (BioLegend Cat. No. 124307)
AB_2073556 (BioLegend Cat. No. 124308)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/22/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_PE_030308
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
  • 10Fdot9G2_PE_030308
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
124307 25 µg DKK393
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124308 100 µg DKK1147
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  2. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  3. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  4. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  5. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  6. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  7. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  8. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  9. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  10. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  11. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  12. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  13. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  14. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  15. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  16. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  17. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  18. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  19. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  20. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  21. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  22. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  23. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  24. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  25. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  26. Shi J, et al. 2018. Immunity. 49:264. PubMed
  27. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  28. Lu SX, et al. 2021. Cell. . PubMed
  29. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  30. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  31. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  32. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  33. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  34. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  35. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  36. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  37. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  38. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  39. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  40. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  41. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  42. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  43. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  44. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  45. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  46. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  47. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  48. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  49. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  50. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  51. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  52. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  53. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  54. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  55. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  56. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  57. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  58. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  59. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  60. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  61. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  62. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  63. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  64. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  65. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  66. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  67. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  68. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  69. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  70. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  71. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  72. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  73. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  74. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  75. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  76. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  77. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  78. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  79. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  80. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  81. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  82. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  83. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  84. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  85. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  86. Zheng Y, et al. 2022. Transl Res. :. PubMed
  87. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  88. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  89. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  90. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  91. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  92. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  93. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  94. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  95. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  96. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  97. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  98. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  99. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  100. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  101. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  102. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  103. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  104. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  105. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  106. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  107. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  108. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  109. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  110. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  111. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  112. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  113. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  114. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  115. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  116. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  117. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  118. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  119. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  120. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  121. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  122. Shi J, et al. 2018. Immunity. 49:264. PubMed
  123. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  124. Lu SX, et al. 2021. Cell. . PubMed
  125. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  126. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  127. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  128. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  129. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  130. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  131. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  132. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  133. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  134. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  135. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  136. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  137. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  138. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  139. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  140. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  141. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  142. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  143. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  144. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  145. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  146. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  147. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  148. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  149. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  150. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  151. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  152. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  153. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  154. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  155. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  156. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  157. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  158. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  159. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  160. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  161. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  162. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  163. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  164. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  165. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  166. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  167. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  168. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  169. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  170. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  171. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  172. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  173. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  174. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  175. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  176. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  177. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  178. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  179. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  180. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  181. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  182. Zheng Y, et al. 2022. Transl Res. :. PubMed
  183. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  184. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  185. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  186. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  187. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  188. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  189. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  190. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  191. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  192. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_2073557 (BioLegend Cat. No. 124307)
AB_2073556 (BioLegend Cat. No. 124308)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/22/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account